Reviewing Alliqua Biomedical (ALQA) & Ocular Therapeutix (NASDAQ:OCUL)

Alliqua Biomedical (NASDAQ: ALQA) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of current recommendations for Alliqua Biomedical and Ocular Therapeutix, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alliqua Biomedical 0 1 2 0 2.67
Ocular Therapeutix 0 2 4 0 2.67

Alliqua Biomedical presently has a consensus target price of $10.10, indicating a potential upside of 397.54%. Ocular Therapeutix has a consensus target price of $20.67, indicating a potential upside of 269.05%. Given Alliqua Biomedical’s higher probable upside, equities research analysts plainly believe Alliqua Biomedical is more favorable than Ocular Therapeutix.

Earnings and Valuation

This table compares Alliqua Biomedical and Ocular Therapeutix’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alliqua Biomedical $18.24 million 0.56 -$28.24 million ($9.86) -0.21
Ocular Therapeutix $1.89 million 87.23 -$44.70 million ($2.28) -2.46

Alliqua Biomedical has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Alliqua Biomedical, indicating that it is currently the more affordable of the two stocks.


This table compares Alliqua Biomedical and Ocular Therapeutix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alliqua Biomedical -155.55% -110.42% -65.28%
Ocular Therapeutix -3,241.19% -126.31% -81.51%

Risk and Volatility

Alliqua Biomedical has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500.

Insider & Institutional Ownership

52.9% of Ocular Therapeutix shares are owned by institutional investors. 15.8% of Alliqua Biomedical shares are owned by company insiders. Comparatively, 26.1% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


Alliqua Biomedical beats Ocular Therapeutix on 7 of the 13 factors compared between the two stocks.

About Alliqua Biomedical

Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers SilverSeal.

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with's FREE daily email newsletter.

Leave a Reply